SEOM Clinical guidelines for the treatment of metastatic prostate cancer

• Autores: Javier Cassinello Espinosa, Miguel Ángel Climent Durán, Aránzazu González del Alba Baamonde, Begoña Mellado, Juan Antonio Virizuela Echaburu
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 12, 2014, págs. 1060-1066
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently required.